Why Weight Loss Clinic
Insurance Falls Short

Most weight loss clinic liability insurance was not built for what happened in 2025. The Food and Drug Administration ended the semaglutide shortage designation, and the compounding pharmacies that had been filling prescriptions legally under shortage provisions were told to wind down. For the weight loss and metabolic medicine practices that had built patient programs around compounded semaglutide and tirzepatide, that was a supply chain problem. What it also turned out to be was an insurance problem. Carriers that were already uncomfortable with this practice model used the regulatory shift to tighten their policy language. And practice owners who went looking for coverage found that the weight loss clinic liability insurance they had been paying for did not quite cover the business they were actually running.

That disruption landed on top of an insurance market that was already a poor fit for this practice model. A regulatory shift that narrowed the product supply, combined with a commercial market that had been quietly limiting its exposure to injectable weight loss medicine, left a lot of practice owners with a coverage gap they had not seen coming.

Here is the short version before the detail: if your operation runs cleaner than the commercial market assumes, the premiums you have been paying are building a carrier's underwriting profit. A captive changes that. The surplus stays in a company you own. The rest of this article explains the coverage gaps, what a captive writes for this practice model, and why the economics work the way they do.

The Compounding Crackdown and What It Exposed

The speed at which semaglutide and tirzepatide reshaped outpatient medicine is genuinely unusual. These glucagon-like peptide-1 receptor agonists went from relatively specialized diabetes drugs to among the most prescribed medications in the country in roughly three years. The result was a category of practice, the dedicated weight loss and metabolic medicine clinic, that did not exist at scale five years ago and now represents one of the fastest-growing segments in cash-pay medicine.

Growth that fast creates insurance problems. When a practice model expands faster than underwriters can build actuarial experience with it, the commercial market's response is to price conservatively and add exclusions. That is not irresponsible. It is how insurance works when claims data is thin. But for the practices on the receiving end, conservative pricing on a category with thin data means overpaying for coverage that may not respond the way they expect when something actually goes wrong.

The Food and Drug Administration's compounding enforcement accelerated that dynamic. When shortage designations ended and enforcement ramped up, some commercial carriers used the moment to revisit their policy language. Product liability provisions that referenced compounded medications got tighter. Regulatory investigation coverage, already inconsistent across policies, became harder to find at meaningful limits. And practices that had been operating in a legally ambiguous supply chain found themselves shopping for coverage in a market that had just watched their business model take a regulatory hit.

The coverage problem did not start with the crackdown. It was already there. The crackdown just made it visible.

What the Commercial Market Was Already Getting Wrong

Cash-pay weight loss clinics combine three things that commercial underwriters handle badly when they appear together: a revenue model with no billing infrastructure backstop, a product component in the form of compounded or branded injectables, and a marketing environment that has drawn regulatory attention. Standard policy forms were built around a different kind of medical practice, and the fit problems are specific.

First, these practices operate without an insurance billing relationship. A traditional medical practice has a revenue tail when it closes or faces a disruption: pending claims with insurers, scheduled procedures, referral pipelines. A cash-pay practice has none of that. Revenue is entirely dependent on patient volume. Patient volume stops immediately when the doors close for any reason. Standard business interruption policies are designed around a business with billing cycles and receivables. They are not designed for this.

Second, the product component creates a coverage gap at the intersection of professional liability and products liability. A practice that administers compounded or branded injectables is functioning partly as a medical practice and partly as a products distribution point. That intersection is an area where coverage gaps are common and often undisclosed until a claim tests them.

Third, the marketing exposure falls into a regulatory defense category that standard policies handle inconsistently. Weight loss medicine has drawn scrutiny from the Federal Trade Commission for efficacy claims and testimonials. A formal Federal Trade Commission inquiry is expensive to defend and does not fit cleanly under professional liability. Standard policies either exclude it, sublimit it severely, or cover it in ways that leave the practice significantly exposed.

Commercial underwriters look at this practice model and see: injectables, compounded drugs, marketing claims risk, and a regulatory environment in flux. The pricing reflects all of that uncertainty. What it does not reflect is what the inside of a well-run practice actually looks like: careful patient screening, documented consent processes, controlled injection protocols, and clinical outcomes tracking that most physician offices do not maintain with the same rigor. You are paying for the category's risk profile. You are not being priced for yours.

The Three Coverage Gaps That Actually Hurt

Not every coverage gap matters equally. Some are theoretical. Some show up at exactly the wrong moment. For weight loss and metabolic medicine clinics, three gaps consistently appear in coverage reviews as the ones that cause real problems.

The first is product liability for compounded injectables. Many general liability policies exclude products derived from compounding pharmacies, or require a separate endorsement that the carrier is reluctant to write for this practice type. When a patient experiences a serious adverse event traced to a compounded injectable, the practice's first call to their carrier may be the moment they learn that the policy they have been paying for does not cover the product at the center of the claim. A single products liability claim involving a compounded injectable, even one that resolves favorably, commonly generates $100,000 to $400,000 in legal defense and expert costs before any settlement is on the table.

The second is regulatory investigation defense at meaningful limits. A formal investigation by the Food and Drug Administration, the Federal Trade Commission, or a state medical board typically costs $75,000 to $250,000 in legal defense before any resolution. Standard professional liability policies, when they include regulatory coverage at all, often cap it at $25,000 or $50,000. That covers a few weeks of legal fees. The investigation continues for months regardless of whether the coverage runs out.

The third is business interruption calibrated to a cash-pay practice. Standard business interruption coverage imposes waiting periods, calculates restoration periods based on historical revenue curves that assume a billing infrastructure, and caps coverage in ways designed for a practice that has receivables and insurance relationships. A cash-pay weight loss clinic with three locations grossing $3 million per year has zero billing buffer. A forced closure for any reason stops revenue on day one.

What a Captive Writes for This Practice Model

A captive insurance company writes for one insured, or a small group of similar insureds, based on the actual risk profile of the people it covers. Its policies are not constrained by what the commercial market is willing to offer at a price that makes actuarial sense for a broad pooled book of business. For a weight loss and metabolic medicine practice, that changes the coverage picture at precisely the points where the commercial market fails.

Product liability for compounded medications administered by licensed practitioners under documented prescribing protocols is a risk a captive can underwrite based on the practice's own protocols, actual claims history, and clinical documentation standards. A practice that screens patients for contraindications, maintains standing orders, documents injection procedures, and tracks adverse event rates is a meaningfully different risk than the category-level exposure a commercial underwriter prices. A captive puts a number on that difference. It prices your premiums against your actual claims record, not the category's.

Regulatory investigation defense with limits that reflect what an investigation actually costs is a coverage category a captive can build to specification. If the practice's regulatory exposure spans Food and Drug Administration inspection, Federal Trade Commission marketing inquiry, and state medical board review, the captive can write a policy covering each of those proceedings at limits that match the realistic legal defense cost, not the standard sublimit that runs out before the first hearing.

Business interruption coverage designed around a cash-pay revenue model, without the waiting periods and billing-infrastructure assumptions that make standard policies inadequate for this practice type, is something a captive can structure from the ground up. The captive insures the actual business, not the template business that standard policy forms were built to cover.

A captive can also write reputational risk coverage as a meaningful, standalone protection rather than a sublimit buried in a cyber endorsement. For a cash-pay practice whose revenue depends entirely on patient trust and word-of-mouth referrals, a serious adverse outcome that becomes public can cost more in revenue over twelve months than the original incident itself.

The Economics of Being a Good Risk in a Bad Category

A well-run weight loss clinic screens patients for contraindications before prescribing, maintains documented consent processes, follows injection protocols that most general practices do not formalize, and tracks outcomes. In actuarial terms, it is a better risk than the category price implies. The commercial carrier charges the category price anyway, because the carrier cannot see inside the practice, and pricing each insured individually is not how commercial insurance pools work.

In a commercial policy, your premiums subsidize the losses of every other practice in the carrier's book of business. When you run clean, the carrier keeps the underwriting profit. When the pool runs hot, your rates go up regardless of your own loss history. You have no stake in the outcome and no ability to price yourself out of a category you do not belong in.

In a captive, you are running that calculation for your own practice. Premiums that do not become claims accumulate as surplus in the captive you own. The underwriting profit belongs to your balance sheet. The investment income on the premium float, the money held between collection and claim payment, belongs to your captive's investment account. The carrier's business model, applied to your own operation, generates returns for you instead of for the carrier.

Here is what that looks like in practice. A three-location weight loss clinic paying $90,000 per year in commercial premiums across all lines, running a disciplined operation with below-average claims for five years, might realistically accumulate $250,000 to $450,000 in captive surplus over that period. That is capital that did not require a bank loan, did not require an equity partner, and was funded entirely by the premiums you were already paying. The only difference is where the profit went.

In a well-structured captive within a risk pool, the captive retains the first layer of risk from your own operations. Losses above that layer are covered by the pool, which shares risk across participating members. That structure makes the captive economically viable at premium volumes well below what a standalone captive would require. And it means your practice has backup capacity for an unusually large claim in an early year, before the captive's surplus has had time to build.

The steady claims from the deductible layer of your coverage, the routine frequency claims the captive handles on its own, serve another function as well. They demonstrate to the Internal Revenue Service that this is a real insurance arrangement, not a tax planning structure dressed up as insurance. Real insurance pays real claims. A captive that has a claims record is a captive that can defend its structure.

The Tax Side of the Equation

Section 831(b) of the Internal Revenue Code allows a qualifying small captive insurer to exclude underwriting income from taxable income up to the annual limit. For 2026, that limit is $2.9 million. A weight loss or metabolic medicine practice that owns a qualifying captive and pays actuarially supported premiums to it may benefit from this exclusion on the captive's underwriting income.

The Internal Revenue Service finalized regulations in January 2025 specifically targeting captive insurance arrangements where the tax benefit was the primary purpose rather than the actual transfer of insurable risk. Those arrangements are designated listed transactions and carry serious penalty exposure for the taxpayers involved and for the promoters who set them up.

A properly structured captive for a weight loss or metabolic medicine practice is built around genuine risk transfer: coverage for real exposures, claims procedures that function as actual insurance, and premium pricing that reflects actuarial analysis of the practice's specific risk profile. That is the structure 3F builds. The 831(b) benefit is an outcome of building the captive correctly, not a planning tool applied to a structure that does not function as insurance. The sequence matters: insurance function first, tax benefit as a result.

Do You Qualify?

The conversation is worth having if several of these sound familiar:

●      You spend $50,000 or more per year on commercial insurance premiums across professional liability, general liability, and products coverage. That is 3F's threshold for this practice type. The general standard for most industries is $250,000, but cash-pay weight loss and metabolic medicine practices qualify at a lower floor because commercial pricing in this market is structurally inflated, and the captive math works at smaller premium volumes than it would for a conventional business.

●      You administer compounded medications, including compounded semaglutide, tirzepatide, or other injectables, and you are not certain that your current general liability policy covers product claims arising from those medications.

●      You have experienced a marketing inquiry, a patient complaint that escalated to a board contact, or a regulatory communication from the Food and Drug Administration, and you discovered that your policy's regulatory defense coverage was not what you expected.

●      You have more than one location, or you are actively expanding, and you recognize that your commercial coverage was priced and written for an earlier version of your practice.

●      You want the premiums that do not become claims to build surplus in a company you own, instead of funding a carrier's underwriting margin.

If most of those apply, a coverage review is the right starting point. We read the policies, identify the gaps specific to your practice model, and tell you plainly whether a captive structure makes economic sense for your operation. If the math does not work yet, you leave knowing exactly what your program covers and where it falls short.

Captive insurance for weight loss and metabolic medicine clinics is a newer application of an established structure. The practice model is new. The coverage gaps are real. And the structure that addresses them has been used by well-managed businesses across industries for decades. 3F Captive Services works with cash-pay medical practices. Start at 3fcaptiveservices.com.

Sources

[1] U.S. Food and Drug Administration. Compounded Drug Products That Are Copies of Commercially Available Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act, Guidance for Industry. 2024 and 2025 updates. https://www.fda.gov

[2] Federal Trade Commission. Policy Statement on Deceptive or Unfair Conduct or Practices in Weight Loss Advertising. Federal Trade Commission enforcement actions against weight loss marketing claims, 2023-2026.

[3] Internal Revenue Code Section 831(b). Internal Revenue Service final regulations on micro-captive listed transactions, effective January 2025. 2026 annual premium limit: $2.9 million.

[4] IQVIA Institute for Human Data Science. The Use of Medicines in the United States 2024: Usage and Spending Trends and Outlook to 2028. Glucagon-like peptide-1 receptor agonist prescribing and market growth data.

[5] American Medical Association. 2026 Survey on Cash-Pay Practice Economics and Insurance Adequacy.

‍